Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.
AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
Roche's Q3 pharma sales rose a healthy 7%, although the first signs of weakness for blockbuster product Xolair are a warning of tougher times ahead.
US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
CSL has named Deborah Waterhouse as its new chief executive, on the same day her departure from the same role at ViiV was announced.
Editor's Picks
